Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol for a multicentre, parallel, randomised, controlled trial on the effect of sweeteners and sweetness enhancers on health, obesity and safety in overweight adults and children: the SWEET project.
Kjølbæk L, Manios Y, Blaak EE, Martínez JA, Feskens EJM, Finlayson G, Andersen SSH, Reppas K, Navas-Carretero S, Adam TC, Hodgkins CE, Del Álamo M, Lam T, Moshoyiannis H, Halford JCG, Harrold JA, Raben A. Kjølbæk L, et al. Among authors: del alamo m. BMJ Open. 2022 Oct 12;12(10):e061075. doi: 10.1136/bmjopen-2022-061075. BMJ Open. 2022. PMID: 36223962 Free PMC article.
Effect of sweeteners and sweetness enhancers on weight management and gut microbiota composition in individuals with overweight or obesity: the SWEET study.
Pang MD, Kjølbæk L, Bastings JJAJ, Andersen SSH, Umanets A, Sost MM, Navas-Carretero S, Reppas K, Finlayson G, Hodgkins CE, Del Álamo M, Lam T, Moshoyiannis H, Feskens EJM, Adam TCM, Goossens GH, Halford JCG, Harrold JA, Manios Y, Martinez JA, Blaak EE, Raben A. Pang MD, et al. Among authors: del alamo m. Nat Metab. 2025 Oct;7(10):2083-2098. doi: 10.1038/s42255-025-01381-z. Epub 2025 Oct 7. Nat Metab. 2025. PMID: 41057614 Free PMC article. Clinical Trial.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Among authors: del alamo m. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
Transient Extensive Edema as a Rare Complication of MRgFUS Thalamotomy.
Ortiz-Zacarias D, Natera-Villalba E, Pineda-Pardo JA, Jiménez T, Duque-Taura A, Rodriguez-Rojas R, Del Álamo M, Martínez-Fernández R. Ortiz-Zacarias D, et al. Among authors: del alamo m. Mov Disord Clin Pract. 2026 Mar 4. doi: 10.1002/mdc3.70582. Online ahead of print. Mov Disord Clin Pract. 2026. PMID: 41782223 No abstract available.
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).
Buzón-Martín L, Montes ML, Pedrero R, Galindo MJ, Santacreu-Guerrero M, Alemán MR, Torralba M, Díaz de Santiago A, Fanjul F, Rodríguez A, Cabello A, Crusells MJ, Navarro MDC, Aguilera M, Hidalgo-Tenorio C, Morano-Amado LE, Vinuesa D, De Andres C, Bernal-Morell E, Martínez-Álvarez RM, Cabello-Clotet N, Tiraboschi J, Montero MDC, Vivancos-Gallego MJ, Díez C, Calderón R, De Zárraga MA, Gisbert L, Romero-Palacios A, Cabo R, Soler JF, Sepúlveda MA, Sánchez-Guirao AJ, Escrich C, Arnaiz De Las Revillas F, Ferreira E, Valentín B, Lérida A, Llenas-García J, Gómez A, Losa JE, Alonso B, Sanz J, Masiá M, Pernas H, Corte JJ, Garcinuño MÁ, Gainzarain JC, Estébanez M, García-Navarro MDM, Barragán P, Ramos N, Clavero M, Millán M, Del Álamo M, Egido M, De La Calle B, Ferrero OL, Troya J. Buzón-Martín L, et al. Among authors: del alamo m. J Antimicrob Chemother. 2025 Dec 2;80(12):3438-3451. doi: 10.1093/jac/dkaf389. J Antimicrob Chemother. 2025. PMID: 41128149
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.
Troya J, Montes ML, Galindo MJ, Santiago AD, Lagarde M, Rodríguez D, Rodríguez A, Crussels MJ, Torralba M, Hidalgo C, Fanjul F, Soler JF, Gisbert L, Díez C, Pérez D, Romero A, Ferreira EM, Cabo R, Rúiz-Alonso N, Escrich C, Sepúlveda MA, Padilla S, Corte JJ, Pedrero-Tomé R; RELATIVITY Group; Buzón L. Troya J, et al. HIV Med. 2026 Jan;27(1):58-73. doi: 10.1111/hiv.70114. Epub 2025 Oct 21. HIV Med. 2026. PMID: 41118425
97 results